MBX
MBX Biosciences, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$61.72
+0.49%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -32.8%
- EBIT
- -36.2%
- EPS
- -4.3%
- Free cash flow
- -18.8%
- Operating cash flow
- -16.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -54.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -40.6%
- EBIT
- -43.8%
- Net income
- -40.5%
- EPS
- -28.6%
- Free cash flow
- -47.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026